GLP-1 in Aesthetics: Compounding, Sourcing & Legal Status

Compounding of FDA-approved drugs is generally prohibited under federal law unless the FDA declares a shortage. Semaglutide and tirzepatide have been subject to intermittent shortage declarations, which temporarily permit licensed pharmacies to compound these drugs. However, shortage status is fluid and announced via FDA drug shortage database updates. As of mid-2026, you must verify current status directly on the FDA's official shortage list (fda.gov/drugs/drug-shortages). If no shortage is declared, compounding is illegal. Even if a shortage is declared, compounding is restricted to licensed 503(b) outsourcing facilities or 503(a) pharmacies operating under state pharmacy law—not to practices. Many practices have sourced compounded GLP-1s from third-party compounding pharmacies; this arrangement does not shield you from liability if the pharmacy operates outside legal bounds or if the shortage declaration lapses. Check your pharmacy partner's DEA and state pharmacy board license, and request written confirmation that they are compounding under an active shortage declaration.

Prescribing or administering GLP-1s for aesthetic (non-medical) purposes sits outside the approved indication and may violate state medical board regulations on off-label use and standard of care. State medical boards vary widely: some have issued guidance permitting off-label GLP-1 prescribing for weight loss in the context of aesthetic practice (e.g., to optimize body contouring outcomes); others have remained silent; a few have warned against it. Before offering GLP-1s, contact your state medical board directly and request written guidance on whether prescribing semaglutide or tirzepatide for weight loss in an aesthetic practice is permitted. Document this communication. If you are a nurse injector or physician assistant, verify your state's delegation and supervision rules—some states require direct physician oversight of GLP-1 prescribing, while others permit independent prescribing by advanced practitioners. Do not rely on peer practice or informal consensus; board enforcement is individual and retroactive.

Offering compounded GLP-1s introduces liability exposure distinct from branded injectables. Compounded drugs lack FDA manufacturing oversight, stability data, and sterility assurance equivalent to FDA-approved products. Patients must be informed in writing that the drug is compounded, not FDA-approved for aesthetic use, and carries unknown risks. Include this in your consent form and document the discussion. Additionally, if a patient experiences an adverse event (nausea, pancreatitis, thyroid concerns, injection-site reaction), you are obligated to report it to MedWatch (FDA's adverse event system) if it is serious or unexpected. Compounded products are often not tracked in national pharmacovigilance systems, so your report may be the only signal. Failure to report can result in FDA warning letters or state board discipline. Maintain detailed records of all GLP-1 administrations, including lot numbers, pharmacy source, patient weight/metabolic markers, and any adverse events. Consider requiring patients to sign an acknowledgment that they understand the compounded status and off-label use.

Compounded GLP-1 supply is fragmented and subject to pharmacy-level disruptions. If your compounding pharmacy loses its license, closes, or stops compounding due to shortage declaration lapses, your supply evaporates. Some practices have contracted directly with 503(b) outsourcing facilities; others source through group purchasing organizations (GPOs) or wholesale distributors. Verify that your supplier is licensed and compliant: request their DEA registration, state pharmacy board license, and proof of compliance with USP <797> standards (sterility and compounding). Ask whether they carry product liability insurance and whether they will indemnify you if their product causes harm. Do not assume a lower price indicates better value—it may indicate corner-cutting on quality or compliance. Branded semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) remain in variable supply; if you can source branded product at reasonable cost, it eliminates compounding risk and provides FDA manufacturing assurance. Compare per-dose cost and supply reliability before committing to compounded sourcing.

The FDA and state medical boards have begun targeting practices offering compounded GLP-1s without clear medical indication or proper oversight. Warning letters have been issued to practices and compounding pharmacies for marketing GLP-1s for cosmetic weight loss without adequate medical supervision. State boards have disciplined physicians for prescribing compounded semaglutide to patients without documented metabolic workup, baseline weight, or follow-up monitoring. The FTC has also scrutinized marketing claims (e.g., "rapid weight loss" or "safe for all patients") as potentially deceptive. Enforcement is accelerating as GLP-1 use in aesthetics becomes more visible. To minimize risk: document a legitimate medical indication (obesity, metabolic syndrome, or weight loss to optimize surgical outcome); obtain baseline labs (fasting glucose, A1C, lipids, renal function); establish a monitoring protocol (follow-up visits, weight checks, adverse event screening); and avoid marketing claims that overstate efficacy or downplay risks. If you receive a board inquiry or FDA letter, consult an attorney immediately—do not respond without counsel.

Before offering GLP-1s, complete this checklist: (1) Verify current FDA shortage status for semaglutide and tirzepatide on fda.gov/drugs/drug-shortages; (2) Obtain written guidance from your state medical board on off-label GLP-1 prescribing in aesthetic practice; (3) Confirm your compounding pharmacy's DEA and state pharmacy board licenses and USP <797> compliance; (4) Request written confirmation that the pharmacy is compounding under an active shortage declaration; (5) Develop a written protocol for patient selection, baseline assessment, informed consent, monitoring, and adverse event reporting; (6) Update your malpractice insurance carrier and confirm coverage for compounded drug administration; (7) Create a detailed consent form disclosing compounded status, off-label use, and known risks; (8) Establish a patient registry with lot numbers, dates, doses, and outcomes; (9) Train staff on MedWatch reporting; (10) Review your protocol annually and adjust for regulatory changes. Document all steps and retain records for at least 7 years.